A new drug called elisrasib has shown promising results in treating advanced lung cancer with a specific genetic mutation (KRAS G12C).
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer
Elisrasib Drug name
NSCLC With KRAS G12C Mutation Cancer type
KRAS G12C Inhibitor Drug class
Advanced/Metastatic Cancer Patient group